Current and emerging mechanical minimally invasive therapies for benign prostatic obstruction.

LUTS benign prostatic obstruction minimally invasive therapies transurethral resection of the prostate

Journal

Therapeutic advances in urology
ISSN: 1756-2872
Titre abrégé: Ther Adv Urol
Pays: England
ID NLM: 101487328

Informations de publication

Date de publication:
Historique:
received: 27 08 2018
accepted: 18 12 2018
entrez: 23 2 2019
pubmed: 23 2 2019
medline: 23 2 2019
Statut: epublish

Résumé

Transurethral resection of the prostate (TURP) is considered the 'gold standard' for the surgical management of lower urinary tract symptoms (LUTS) due to benign prostatic obstruction (BPO). However, during recent years TURP has been challenged by several minimally invasive therapies (MITs). The reasons for the development of these MITs are the need for anesthesia and the rather unchanged morbidity of TURP, including ejaculation disorders. Mechanical MITs may represent an attractive option for treating LUTS/BPO by using mechanical forces to maintain urethral patency without cutting, ablating, heating or removing prostatic tissue. The present paper provides an update on currently available mechanical devices for the treatment of LUTS/BPO including the prostatic urethral lift (PUL), the temporary implantable nitinol device, and new intraprostatic implants. It analyzes the evidence for their safety, tolerability, and efficacy in clinical practice and aims to define those subpopulations of patients who will benefit from these MITs. It is obvious that there is a wide variation in the degree of mature of the available mechanical MITs. Time and high-quality long-term studies will decide which of these therapies will be accepted by patients and urologists. At the moment, PUL is claiming its position in the armamentarium of BPO treatment.

Identifiants

pubmed: 30792821
doi: 10.1177/1756287219828971
pii: 10.1177_1756287219828971
pmc: PMC6376539
doi:

Types de publication

Journal Article Review

Langues

eng

Pagination

1756287219828971

Déclaration de conflit d'intérêts

Conflict of interest statement: The authors declare that there is no conflict of interest.

Références

Curr Urol Rep. 2001 Aug;2(4):277-84
pubmed: 12084252
BJU Int. 2004 Feb;93(3):346-8
pubmed: 14764134
BJU Int. 2006 Oct;98(4):806-10
pubmed: 16879446
J Urol. 2007 May;177(5):1619-24
pubmed: 17437773
J Endourol. 2007 Sep;21(9):1093-6
pubmed: 17941793
Surgery. 2008 Feb;143(2):206-15
pubmed: 18242337
J Sex Med. 2012 Feb;9(2):568-75
pubmed: 22172161
Urology. 2012 Jan;79(1):5-11
pubmed: 22202539
Eur Urol. 2013 Aug;64(2):292-9
pubmed: 23357348
Eur Urol. 2013 Sep;64(3):493-501
pubmed: 23465519
J Urol. 2013 Dec;190(6):2161-7
pubmed: 23764081
J Sex Med. 2014 Jan;11(1):279-87
pubmed: 24119101
Can J Urol. 2014 Feb;21(1):7094-101
pubmed: 24529008
BJU Int. 2015 Aug;116(2):278-87
pubmed: 25382816
Eur Urol. 2015 Apr;67(4):704-13
pubmed: 25466940
Eur Urol. 2015 Oct;68(4):643-52
pubmed: 25937539
Curr Bladder Dysfunct Rep. 2015;10(2):186-192
pubmed: 25984251
Can J Urol. 2015 Jun;22(3):7772-82
pubmed: 26068624
Prostate Int. 2015 Mar;3(1):1-5
pubmed: 26157759
Appl Health Econ Health Policy. 2016 Oct;14(5):515-26
pubmed: 26832146
Urology. 2016 Nov;97:20-24
pubmed: 27208817
BJU Int. 2017 May;119(5):767-775
pubmed: 27862831
Can J Urol. 2017 Jun;24(3):8802-8813
pubmed: 28646935
BJU Int. 2018 Jul;122(1):106-112
pubmed: 29359881
J Urol. 2018 Sep;200(3):612-619
pubmed: 29775639
Curr Urol. 2018 Jun;11(4):206-211
pubmed: 29997464
Eur Urol Focus. 2018 Oct 4;:null
pubmed: 30293945

Auteurs

Petros Sountoulides (P)

Aristotle University of Thessaloniki, Department of Urology, Thessaloniki, Greece.

Anastasios Karatzas (A)

University of Thessaly, Faculty of Medicine, Department of Urology, Larissa, Greece.

Stavros Gravas (S)

University of Thessaly, Faculty of Medicine, Department of Urology, Feidiou 6-8, 41221, Larissa, Greece.

Classifications MeSH